Swine Parvovirus Vaccine, Inactivated (Strain CP-99) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a purified inactivated whole-virus antigen intended exclusively for further manufacture of veterinary immunobiological products. The product is distributed under three model identifiers: SPV-CP99-API-LQ for the sterile aqueous concentrate, SPV-CP99-API-LYO for the lyophilized powder, and SPV-CP99-API-UF for the ultrafiltered post-purification intermediate. The liquid presentation is a milky-white to faintly opalescent suspension in phosphate-buffered saline, pH 7.2–7.6, osmolality 260–320 mOsmol/kg, with a pre-inactivation virus titer of not less than 10^7.5 TCID₅₀/mL in PK-15 cell cultures. The lyophilized presentation is compounded with 2.0–5.0% w/v mannitol or sucrose and dried to residual moisture not exceeding 3.0% w/w. The API is not intended for direct administration.

The dosage-form descriptors in the listed title include oral solid and feed-based forms. For an inactivated parvovirus antigen, oral delivery is not supported by the parenteral immunogenicity of the whole-virus particle, and published data for this specific configuration is limited. Tablets, capsules, granules, and premix should be regarded as packaging or logistics designations unless a separate mucosal immunogenicity and antigen-protection development package demonstrates viability.

The aqueous concentrate is stored at 2–8 °C with a manufacturer-assigned shelf life of 24 months in closed sterile containers. The lyophilized powder is stored at 2–8 °C or −20 °C for extended stability. Repeated freeze-thaw cycles of the liquid concentrate are not recommended because aggregated virus particles may reduce sterile-filter throughput and lower post-formulation potency.

What Specifications Govern Release of Inactivated Strain CP-99 Antigen?

Release of the inactivated strain CP-99 API is controlled through a panel of identity, safety, purity, and antigen-content tests. The following matrix lists the controls applied to the API before transfer to finished vaccine manufacturing.

Batch release documentation includes the above panel, but the finished vaccine manufacturer retains responsibility for adjuvant compatibility, antigen payload per dose, and final sterile filtration. The API specification is not a finished-product potency claim; identical antigen concentrations can yield different final potency depending on adjuvant selection and dilution.

After virus propagation in PK-15 cell monolayers, clarification by depth filtration and concentration by tangential-flow filtration is carried out. Process development data show that PPV CP-99 harvests are shear-labile; transmembrane pressure above 0.6 bar on a 300 kDa polyethersulfone membrane causes flux decline and may reduce hemagglutination titer. The recommended TMP window is 0.3–0.6 bar with a crossflow rate of 4–6 L/min/m². Inactivation by binary ethyleneimine at 0.01–0.02 M for 24–48 h at 37 °C is followed by neutralization with sodium thiosulfate. pH control during neutralization is critical; excursions above 8.0 can cause antigen aggregation and loss of adsorption competence. In a 100 L stainless-steel inactivation vessel, sparged mixing at 80–120 rpm and controlled addition of 1 M sodium thiosulfate maintains pH between 7.0 and 7.5.

Validation of inactivation requires a kinetic curve showing at least 4 log₁₀ reduction within the first 8 h and the absence of residual virus in three blind passages. If the inactivation curve deviates from first-order kinetics after 24 h, the run is rejected because the trailing fraction may contain aggregated virus protected from the inactivating agent. pH re-adjustment during inactivation is avoided because repeated alkali injection can raise local pH above 8.5 and cause capsid dissociation.

Residual host-cell DNA is reduced by benzonase digestion at 10–25 U/mL for 2–4 h at room temperature before ultrafiltration. Depth filter loading above 60 L/m² for crude PPV harvest may shorten clarification time but increases post-elution turbidity; a two-stage depth filter train with a final 0.45 µm membrane is used. Calculated log-reduction values for the total downstream train should meet or exceed 4 log₁₀ for residual process impurities, but the critical safety parameter remains the absence of residual live virus after inactivation.

Product contact materials should be evaluated for binding of the virus capsid. Silicone tubing, stainless steel 316L, and polyethersulfone membranes are generally compatible. Borosilicate glass can be used for storage, but untreated polystyrene may bind virus under low protein conditions if surfactant is absent.

Adjuvant Adsorption Conditions and Excipient Incompatibilities

Adjuvant adsorption of inactivated CP-99 antigen onto aluminium hydroxide gel is performed at pH 6.8–7.4 and phosphate content below 10 mM in the antigen concentrate. At pH above 8.0, adsorption efficiency can drop below 80% in laboratory stirred-cell studies, and the resulting vaccine may fail potency due to free antigen. The antigen concentrate should not be diluted with phosphate-buffered saline before aluminium hydroxide adsorption because phosphate competes for ligand-exchange sites. Use 0.9% sodium chloride or tris buffer at ionic strength 150 mM.

For oil-emulsion vaccines, the aqueous antigen phase is added to the oil phase under high-shear dispersion using a rotor-stator mixer at 3,000–6,000 rpm for 5–15 min. Droplet size 1–10 µm is maintained; over-emulsification above 10,000 rpm can raise temperature above 37 °C and reduce antigenic integrity. The emulsion should be checked for viscosity and phase separation at 24 h and 72 h after preparation. Avoid cationic surfactants and benzalkonium chloride above 0.01% w/v, which can precipitate viral capsid proteins in the aqueous phase.

Batch-to-batch variance in antigen adsorption is monitored by zeta potential and particle size. A shift in zeta potential from negative to less than −20 mV after adjuvant adsorption may indicate incomplete antigen binding. In one production-scale observation, a 50 L mixing vessel with magnetic drive impeller produced lower adsorption than a bottom-mounted pitch-blade impeller at the same speed because of insufficient axial flow.

A comparison of strain CP-99 with other inactivated porcine parvovirus APIs is most meaningful at the level of purification and release controls, not antigenic strain identity alone. Porcine parvovirus vaccine strains such as NADL-2 share the same neutralizing VP2 epitopes but may differ in cell-culture yield and hemagglutination activity. The CP-99 API is supplied as a concentrated antigen with host-cell protein controlled at not more than 250 ng/mL, whereas published data for comparator APIs often show wider purity ranges; where direct comparability data is absent, head-to-head side-by-side formulation under the same adjuvant and dose is required.

Compared with ready-to-use inactivated parvovirus vaccines that contain adjuvanted antigen, the API product does not include an adjuvant or preservative. This difference reduces incompatibility during downstream formulation but places the final vaccine manufacturer in control of adjuvant and preservative selection. Thimerosal or other mercury-based preservatives should be avoided if the final product is intended for sows in late gestation because of potential toxicity.

Final formulation of the CP-99 antigen requires sequential mixing steps. The antigen concentrate is first diluted with sterile isotonic diluent to the target antigen payload, then pH-adjusted, then combined with adjuvant. Mixing in a 50 L single-use vessel at 100–150 rpm for 15–30 min is typical. Filling operations should maintain temperature at 2–8 °C; the bulk vaccine should not be frozen unless the formulation contains approved cryoprotectants. For freeze-dried final vaccine, the filled vials are chilled to −45 °C at 0.5 °C/min, primary-dried at −25 °C and 0.1 mbar for 18 h, and secondary-dried at 25 °C for 4 h. The target residual moisture is not more than 3.0%.

During final filtration, the maximum filter differential pressure should be below 0.8 bar for polyethersulfone filters; high pressure can force aggregated virus through the membrane or rupture virions. If the pre-filtration HA titer is ≥ 1:512, a post-filtration recovery of ≥ 85% is expected; lower recovery indicates filter adsorption or aggregation. Sterile filtration is typically performed on the antigen concentrate before adjuvant addition, not after the emulsion is formed.

Granules and powders are produced by lyophilization followed by milling through a 0.5 mm screen under dry nitrogen. Moisture uptake must be checked because at relative humidity above 60%, lyophilized PPV antigen becomes hygroscopic and aggregates upon reconstitution. Pre-drying and dry-room handling at RH ≤ 30% are required.

When the API Is Supplied as a Lyophilized Powder

When the API is supplied as a lyophilized powder, rehydration must occur under controlled conditions in a biosafety cabinet or cleanroom. The powder is reconstituted with sterile water for injection at 20–30 °C to the original volume. Reconstitution time should be less than 60 s with gentle swirl; vortex mixing can generate foam and shear strain. The reconstituted concentrate has a usable hold time of 8 h at 2–8 °C before final formulation. After reconstitution, the solution passes through a 0.45 µm prefilter and a 0.22 µm final membrane if terminal sterile filtration is required; filter adsorption of the virus particle should be evaluated by HA titer before and after filtration.

Reconstituted lyophilized API should not be re-frozen. If freezing occurs, the HA titer may drop by 0.5–1.0 log₁₀ and the product should be requalified before use. For granules and powder premixes intended for feed or oral use, the inactivated virus antigen requires encapsulation to survive gastric pH 2.0–3.5 and pepsin exposure. No compendial standard exists for such oral delivery of this antigen, and any claim of oral efficacy must be supported by intestinal IgA and systemic IgG data.

A typical injectable vaccination schedule in gilts and sows uses a 2.0 mL intramuscular dose, two doses 3–4 weeks apart, followed by a booster before breeding.